Biodesix
Biodesix Q4 Revenues up 39 Percent
The firm's improved financial results reflected significant growth in its lung cancer testing business, which includes a nodule risk test and a genomic test for therapy selection.
Biodesix Preliminary Revenues up 39 Percent for Q4, 45 Percent for 2024
The company projected that it grew its revenues by double digits in both diagnostic testing and biopharma and other services.
Biodesix Q3 Revenues up 35 Percent
The company attributed its growth to increased adoption of its lung cancer risk assessment tests, while it highlighted recent and ongoing research supporting those products.
Biodesix Reports 50 Percent Q2 Revenue Jump, Raises Full-Year Guidance
The company reported a 43 percent increase in diagnostic testing revenue, driven primarily by the continued adoption of its Nodify Lung nodule risk assessment tests.
TD Cowen Initiates Coverage of Biodesix With Buy Rating
Analyst Dan Brennan wrote that lung nodule diagnostics is about a $4 billion market that is only about 1 percent penetrated, with Biodesix the only commercial player.